☰

Guido Vanham

Affiliations: 
Universiteit Antwerpen (Belgium) 
Area:
Microbiology Biology, Immunology, Pharmacology, Molecular Biology, Virology Biology
Google:
"Guido Vanham"
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Yven Van Herrewege grad student 2004 Universiteit Antwerpen (Belgium)
Philippe Selhorst grad student 2012 Universiteit Antwerpen (Belgium)

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gupta A, Righi E, Konnova A, et al. (2024) Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV. Journal of Medical Virology. 96: e29820
Su B, Vanham G. (2023) Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals. Aids (London, England). 37: 837-839
Adams P, Fievez V, Schober R, et al. (2021) CD32CD4 memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice. Iscience. 24: 101881
Adams P, Iserentant G, Servais JY, et al. (2020) Cytotoxic CD8+ T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged Peptide Stimulation. Frontiers in Immunology. 11: 622343
Pannus P, Rutsaert S, De Wit S, et al. (2020) Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. Journal of the International Aids Society. 23: e25453
de Jong W, Aerts J, Allard S, et al. (2019) Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 20: 721
Jong W, Leal L, Buyze J, et al. (2019) Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. Vaccines. 7
Pannus P, Vanham G. (2019) Viral Inhibitory Activity of CD8+ T Cells in HIV Infection. Aids Reviews. 21: 115-125
de Jong W, Aerts J, Allard S, et al. (2019) iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 20: 361
Pannus P, Adams P, Willems E, et al. (2019) In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients. Aids (London, England). 33: 387-398
See more...